Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fish oil supplement tested for muscle loss in liver cancer patients

NCT ID NCT07664007

Disease control Sponsor: Instituto de Investigación Sanitaria Aragón Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed trial tested whether a daily EPA (an omega-3 fatty acid) supplement could help preserve muscle mass and reduce inflammation in 18 people with advanced liver cancer that could not be surgically removed. Participants took either the EPA supplement or a placebo for 12 weeks alongside their standard chemotherapy. The study measured changes in muscle mass using CT scans and assessed nutritional status.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
eicosapentaenoic acid (EPA) supplement
What this could lead to
If it works, this could point toward a simple nutritional supplement to help maintain muscle mass and reduce inflammation in people with advanced liver cancer.
What could go wrong
This was a very small, early-stage trial with only 18 participants, so results may not apply widely. The supplement may not provide meaningful benefit over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

18 people

The number who actually took part.

Started

Mar 2019

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants diagnosed with unresectable HCC, candidates for systemic treatment with Sorafenib or similar agents. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Life expectancy \> 8 weeks. * Not eligible for curative treatment (surgical resection/ablative therapy/liver transplantation). * Not having a history of previous or concomitant malignancy except when a disease-free interval \> 5 years had been documented. * Not receiving any other systemic antitumor agents (docetaxel, doxorubicin, irinotecan). Exclusion Criteria: * Allergy to omega-3 acid or fish-derived products. * Psychological or medical conditions that can interfere with study participation or the ability to provide informed consent. * Drug abuse (except for alcohol). * Any experimental therapy within 30 days prior to study entry. * Recurrent epistaxis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cachexia hepatocellular carcinoma Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • Hospital Clínico Universitario Lozano Blesa. IIS Aragón

    Zaragoza, Zaragoza, 50009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.